Rhythm Pharmaceuticals
RYTM
115 hedge funds and large institutions have $1.81B invested in Rhythm Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 42 increasing their positions, 28 reducing their positions, and 12 closing their positions.
117% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 12
50% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 28
23% more capital invested
Capital invested by funds: $1.47B → $1.81B (+$344M)
21% more call options, than puts
Call options by funds: $15.5M | Put options by funds: $12.9M
14% more funds holding
Funds holding: 101 → 115 (+14)
1.01% more ownership
Funds ownership: 109.57% → 110.59% (+1%)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$13.8M |
| 2 |
Alkeon Capital Management
New York
|
+$13.7M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$12.3M |
| 4 |
Goldman Sachs
New York
|
+$10.9M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$48.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$15.4M |
| 3 |
Walleye Capital
New York
|
-$4.69M |
| 4 |
Primecap Management
Pasadena,
California
|
-$2.97M |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$2.44M |
RYTM Hedge Fund Activity: Q4 2022 in Review
115 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Rhythm Pharmaceuticals (RYTM) for Q4 2022, worth a combined $1.81B — up 23% from $1.47B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new RYTM positions and 12 closed out — a net gain of 14 holders — while 42 added to existing stakes and 28 trimmed.
The largest buyer was Polar Capital Holdings, adding an estimated $13.8M. The largest seller was Janus Henderson Group, cutting an estimated $48.4M.
- 115 institutional investors held Rhythm Pharmaceuticals (RYTM) as of Q4 2022, up from 101 in Q3 2022.
- Funds reported $1.81B of Rhythm Pharmaceuticals stock for Q4 2022, up 23% quarter-over-quarter.
- 26 funds opened new Rhythm Pharmaceuticals positions in Q4 2022 and 12 closed out, a net change of +14 holders.
- The largest Rhythm Pharmaceuticals buyer in Q4 2022 was Polar Capital Holdings, an estimated $13.8M added.
- The largest Rhythm Pharmaceuticals seller in Q4 2022 was Janus Henderson Group, an estimated $48.4M sold.
Based on aggregated 13F filings for Q4 2022.